Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-hku-study-on-multi-gene-mutation-drug-matching-for-recurrent-ovarian-cancer-patients-providing-free-pharmacogenomic-analysis-for-100-patients-in-hong-kong
https://www.med.cuhk.edu.hk/press-releases/cuhk-hku-study-on-multi-gene-mutation-drug-matching-for-recurrent-ovarian-cancer-patients-providing-free-pharmacogenomic-analysis-for-100-patients-in-hong-kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

The Faculty of Medicine of The Chinese University of Hong Kong (CUHK) and the Li Ka Shing Faculty of Medicine of The University of Hong Kong (HKU) are going to launch the city’s first collaborative study with the aim of providing expert affordable multi-gene mutation – drug matching for recurrent ovarian cancer patients. The research goal is to help identify a more precise choice of drug, based on tumour DNA characteristics using modern pharmacogenomic analysis. At the same time, the research team will determine the prevalence of potential druggable DNA events in Asian recurrent ovarian cancer patients.  This Hong Kong Cancer Fund-sponsored study will provide free analysis for 100 local patients.

 

Ovarian cancer recurrence can be up to 80% in late stage with no precise regimen

According to the data of the Hong Kong Cancer Registry 2015, ovarian cancer is the 6th most common cancer type for Hong Kong females, with an average of over 500 new cases each year, and ranks 7th in overall cancer mortality rates. There is also an increasing trend in its incidence since the 1980s. The causes of ovarian cancer are still uncertain and early symptoms are not obvious.  34% of patients are in stage III or IV at the time of diagnosis. Standard treatment of ovarian cancer is surgery with proper staging. In late stage cancer, removal of all gross tumours is the goal.  However, for these advanced stage patients, despite such radical treatment, recurrence is common and can be up to 80%.  In the majority of recurrent cases, surgery is not suitable and chemotherapy is the mainstay of treatment.  

 

Prof. Hextan Yuen-Sheung NGAN, Tsao Yin-Kai Professor in Obstetrics and Gynaecology, Chair Professor and Head of the Department of Obstetrics and Gynaecology, Li Ka Shing Faculty of Medicine, HKU said, ‘The response rate of the drug treatment for recurrent patients varies from 20 - 40%. Though we have quite a number of drugs that can be used to treat recurrent ovarian tumour, we do not know which one has the best response.  We therefore need a more precise way of choosing the most effective regimen.’

 

Study aims at helping recurrent ovarian cancer patients to find a drug option based on DNA sequencing multiple genes

Pharmacogenomic analysis can help identify a more precise choice of drug based on tumour DNA characteristics. The analysis first requires tumour DNA to be sequenced for multiple genes which are known to be related to drug responses, followed by professional gene mutation – drug matching.

 

In the past, pharmacogenomic analysis was usually done for one gene at a time (e.g. EGFR mutation for lung cancer to be matched for EGFR inhibitor).  In the last 3 to 5 years, DNA sequencing technology has become more mature and professional gene mutation – drug matching expertise is available in Hong Kong.

 

Prof. Stephen Kwok-Wing TSUI, Professor, School of Biomedical Sciences, Faculty of Medicine, CUHK said, ‘The DNA sequencing technology at CUHK, namely the Next-Generation Sequencing (NGS), can simultaneously sequence multiple genes, hundreds or tens of thousands of genes, in a few hours, which would have taken several months to a year in the past. The advanced technology allows us to perform multi-gene sequencing very quickly and accurately, taking very small amounts of tumour DNA samples (nanograms).’

 

CUHK has established a responder gene-drug database from over 150 clinical studies of ovarian cancers and additional cancers

The CUHK team has established the Responder Gene Panel from the results of over 150 clinical studies of ovarian cancer and additional cancer types from more than 18 countries in the US, Europe and Asia. It is designed to enable pharmacogenomic analysis of patient tumour samples using the NGS technology in Hong Kong. Along with expert drug matching, the Responder Gene Panel can reliably tell the presence or absence of drug-associated gene mutations in a patient’s tumour, which can serve to identify potential drug options for patients based on tumour DNA evidence.

 

The Panel includes all reported ovarian cancer patient DNA mutations that are associated with good and exceptional clinical responses to specific drug treatments, as of 2017. It is estimated that about 30% (or more) of ovarian cancer patients may have these ovarian responder mutations. Any enrolled ovarian cancer patient whose tumours carry these responder DNA mutations will receive a DNA-drug matching research result as genetic evidence and as a reference for drug choice by the patient’s physician-in-charge. The patients can also choose to receive any information associated with additional cancer types as an additional record.

 

Prof. Vivian Wai Yan LUI, Associate Professor, School of Biomedical Sciences, Faculty of Medicine, CUHK, an expert in cancer pharmacogenomics said, ‘A similar approach has been widely adopted in more advanced countries such as the US. Our goal is to promote the use of multi-gene pharmacogenomics analysis in Hong Kong ovarian cancer patients to help identify tumour DNA events that may guide precise drug choice quickly. At the same time, we can determine the frequency of occurrence of these potential druggable DNA events in Asian ovarian cancer patients. Our study comprises a team of experts from Hong Kong, the US, and the UK on cancer, precision medicine and medication. The study will also follow-up on patients for up to 2 years to investigate the feasibility of pharmacogenomics in Hong Kong.’

 

The study is sponsored by Hong Kong Cancer Fund. It will officially start on 8 December this year, with the target of recruiting 100 patients in Hong Kong over the next 16 months. Interested patients can call 3943-5382 or email to ovcamut@cuhk.edu.hk. For details, please refer to the project website: http://cuhk.edu.hk/proj/ovcamut

 

The Faculty of Medicine of CUHK and the Li Ka Shing Faculty of Medicine of HKU launch the city’s first collaborative study with the aim of providing expert affordable multi-gene mutation – drug matching for recurrent ovarian cancer patients. From left: Prof. Hextan Yuen-Sheung NGAN, Tsao Yin-Kai Professor in Obstetrics and Gynaecology, Chair Professor and Head of the Department of Obstetrics and Gynaecology, Li Ka Shing Faculty of Medicine, HKU; Prof. Stephen Kwok-Wing TSUI, Professor, School of Biomedical Sciences and Prof. Vivian Wai Yan LUI, Associate Professor, School of Biomedical Sciences, Faculty of Medicine, CUHK.

The Faculty of Medicine of CUHK and the Li Ka Shing Faculty of Medicine of HKU launch the city’s first collaborative study with the aim of providing expert affordable multi-gene mutation – drug matching for recurrent ovarian cancer patients. From left: Prof. Hextan Yuen-Sheung NGAN, Tsao Yin-Kai Professor in Obstetrics and Gynaecology, Chair Professor and Head of the Department of Obstetrics and Gynaecology, Li Ka Shing Faculty of Medicine, HKU; Prof. Stephen Kwok-Wing TSUI, Professor, School of Biomedical Sciences and Prof. Vivian Wai Yan LUI, Associate Professor, School of Biomedical Sciences, Faculty of Medicine, CUHK.

Professor LUI wants to promote the use of multi-gene pharmacogenomics analysis for Hong Kong ovarian cancer patients to help identify tumour DNA events that may guide precise drug choice efficiently.

Professor LUI wants to promote the use of multi-gene pharmacogenomics analysis for Hong Kong ovarian cancer patients to help identify tumour DNA events that may guide precise drug choice efficiently.

Professor TSUI says CUHK's ‘Next-Generation Sequencing’ technology can perform multi-gene sequencing very quickly and accurately with only small amounts of tumour DNA samples.

Professor TSUI says CUHK's ‘Next-Generation Sequencing’ technology can perform multi-gene sequencing very quickly and accurately with only small amounts of tumour DNA samples.

Professor NGAN says despite removal of all gross tumours, ovarian cancer recurrence would be up to 80% in late stage and therefore precise regimen is needed.

Professor NGAN says despite removal of all gross tumours, ovarian cancer recurrence would be up to 80% in late stage and therefore precise regimen is needed.

More Press Releases

Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK Unveils Genome of Dermatophagoides farinae Casting New Light on Diagnosis and Interventions of Inhalant Allergies

CUHK Unveils Genome of Dermatophagoides farinae Casting New Light on Diagnosis and Interventions of Inhalant Allergies

Research
CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

Research
A Global Study Led by CU Medicine and HKUMed Discovers  a Hepatitis C Virus Drug as Potent Treatment for COVID-19

A Global Study Led by CU Medicine and HKUMed Discovers a Hepatitis C Virus Drug as Potent Treatment for COVID-19

Research
CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

Research
A Joint Study by CUHK, PolyU and Western Sydney University Discovers how the Nervous System of Human Runners Generates More Energetically Efficient Running Forms

A Joint Study by CUHK, PolyU and Western Sydney University Discovers how the Nervous System of Human Runners Generates More Energetically Efficient Running Forms

Research
CUHK Researchers Uncover Diabetes as a Potential Risk Factor for COVID-19,  and Possible Mechanisms

CUHK Researchers Uncover Diabetes as a Potential Risk Factor for COVID-19, and Possible Mechanisms

Research
CUHK Study Discovers Brain Circuitry That Generates Behavioural Responses to Stress Provide a Basis for Probing Abnormal Repetitive Behaviour Exhibited in Brain Disorders

CUHK Study Discovers Brain Circuitry That Generates Behavioural Responses to Stress Provide a Basis for Probing Abnormal Repetitive Behaviour Exhibited in Brain Disorders

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
CUHK Study Discovers Pathway That Links to Cognitive Flexibility Dopamine Dysregulation May Lead to Ability Impairment

CUHK Study Discovers Pathway That Links to Cognitive Flexibility Dopamine Dysregulation May Lead to Ability Impairment

Research
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Study Discovers an Essential Enzyme to Maintain Body Iron Homeostasis Deficiency Could Cause Excessive Iron Retention and Damage Major Organs

CUHK Study Discovers an Essential Enzyme to Maintain Body Iron Homeostasis Deficiency Could Cause Excessive Iron Retention and Damage Major Organs

Research
CUHK School of Biomedical Sciences Strives to Become the World-leading Biomedical Hub

CUHK School of Biomedical Sciences Strives to Become the World-leading Biomedical Hub

Milestone
10th Palliative Care Symposium for Healthcare Workers in Chinese Population: ‘Succession ‧ Innovation’

10th Palliative Care Symposium for Healthcare Workers in Chinese Population: ‘Succession ‧ Innovation’

Symposium
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK’s Gerald Choa Neuroscience Centre Unveils Mystery of How Brain Learns Motor Skills

CUHK’s Gerald Choa Neuroscience Centre Unveils Mystery of How Brain Learns Motor Skills

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
The 9th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Integrating Palliative Care into General Care: Paving the Way for the Future’

The 9th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Integrating Palliative Care into General Care: Paving the Way for the Future’

Symposium
CUHK-led Study Reveals Novel Mechanism for the Development of Atherosclerosis Setting New Treatment Directions to Cardiovascular Diseases

CUHK-led Study Reveals Novel Mechanism for the Development of Atherosclerosis Setting New Treatment Directions to Cardiovascular Diseases

Research
CUHK Launches World’s First Study on Ovum Ageing and Female Infertility by Using Single-Cell Genomics Technology

CUHK Launches World’s First Study on Ovum Ageing and Female Infertility by Using Single-Cell Genomics Technology

Research
CUHK/International Study Implicates a Gene in Alzheimer’s disease

CUHK/International Study Implicates a Gene in Alzheimer’s disease

Research
The 8th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Advancing Palliative Care in Hong Kong: Opportunities and Challenges’

The 8th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Advancing Palliative Care in Hong Kong: Opportunities and Challenges’

Symposium
The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

Symposium
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
The 6th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care for Geriatric Cancer Patients’

The 6th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care for Geriatric Cancer Patients’

Symposium
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research
CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

Symposium
CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

Surgical advancement
Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Surgical advancement
CUHK and US Experts Collaborate to Provide Clinical Genetic Training to Set up The Territory's First One-Stop Outpatient Genetic Clinic

CUHK and US Experts Collaborate to Provide Clinical Genetic Training to Set up The Territory's First One-Stop Outpatient Genetic Clinic

International collaboration
CUHK Lo Kwee-Seong Integrated Biomedical Sciences Building Opened

CUHK Lo Kwee-Seong Integrated Biomedical Sciences Building Opened

Milestone
CUHK and HKU's Collaborative Research Discovers Novel Epilepsy Genetic Markers

CUHK and HKU's Collaborative Research Discovers Novel Epilepsy Genetic Markers

Research
The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

Symposium
Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.